Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2025 May 7;20(5):e0322873.
doi: 10.1371/journal.pone.0322873. eCollection 2025.

Severe adverse reactions to benzathine penicillin G in rheumatic heart disease: A systematic review and meta-analysis

Eshetie Melese Birru  1   2 , Kefyalew Addis Alene  3   4 , Laurens Manning  5   6 , Kevin T Batty  1   7 , Brioni R Moore  1   6   7
Affiliations
Meta-Analysis

Severe adverse reactions to benzathine penicillin G in rheumatic heart disease: A systematic review and meta-analysis

Eshetie Melese Birru et al. PLoS One. .

Abstract

Background: Fear of severe adverse reaction (SAR) and reluctance of health care providers to administer intramuscular injections are major contributing factors to poor adherence of benzathine penicillin G (BPG) in the management of rheumatic heart disease (RHD). However, data on the risk of SARs following BPG injections for RHD are relatively limited and inconclusive. Our systematic review and meta-analysis aimed to evaluate the incidence of SARs associated with BPG injections used for secondary prophylaxis of RHD.

Methods: A systematic literature search of PubMed, Scopus and Web of Science databases was conducted to identify relevant studies reporting adverse reactions following BPG injections in patients with acute rheumatic fever (ARF) and/or RHD. A random effect meta-analysis was performed to estimate the pooled incidence of SARs.

Result: Nine studies (eight cohort and one randomized controlled trial), comprising 11,587 participants and > 154,760 BPG injections, were included in the analysis. The pooled incidence of SARs was 9.7 per 10,000 cases (95% CI: 0.1-29.2) and 1.1 per 10,000 BPG injections (95% CI: 0.4-2.2). Six fatal reactions were reported (0.05% of patients and 24% of SARs), all occurring in patients with severe RHD.

Conclusion: SARs following BPG injections in patients with ARF or RHD are rare. Our findings highlight the importance of balancing the low rate of SARs against the benefits of BPG in secondary prophylaxis for RHD, particularly in high-risk populations. High-quality longitudinal research and comprehensive adverse reaction reporting are essential to address safety concerns among healthcare providers and patients that impact BPG delivery.

PubMed Disclaimer

Conflict of interest statement

The authors have declared that no competing interests exist.

Figures

Fig 1
Fig 1. PRISMA flow diagram showing literature search and study selection.
Fig 2
Fig 2. Incidence of SARs following BPG injection, per 10,000 cases.
Fig 3
Fig 3. Incidence of SARs per 10,000 BPG injections among ARF and RHD patients.
Fig 4
Fig 4. Incidence of fatal reactions following BPG injection per 10,000 cases.
See this image and copyright information in PMC

References

    1. Carapetis JR, Beaton A, Cunningham MW, Guilherme L, Karthikeyan G, Mayosi BM, et al.. Acute rheumatic fever and rheumatic heart disease. Nat Rev Dis Primers. 2016;2:15084. doi: 10.1038/nrdp.2015.84 - DOI - PMC - PubMed
    1. Ou Z, Yu D, Liang Y, Wu J, He H, Li Y, et al.. Global burden of rheumatic heart disease: trends from 1990 to 2019. Arthritis Res Ther. 2022;24(1):138. doi: 10.1186/s13075-022-02829-3 - DOI - PMC - PubMed
    1. de Dassel JL, Ralph AP, Carapetis JR. Controlling acute rheumatic fever and rheumatic heart disease in developing countries: are we getting closer? Curr Opin Pediatr. 2015;27(1):116–23. doi: 10.1097/MOP.0000000000000164 - DOI - PubMed
    1. Roberts KV, Maguire GP, Brown A, Atkinson DN, Remenyi B, Wheaton G, et al.. Rheumatic heart disease in Indigenous children in northern Australia: differences in prevalence and the challenges of screening. Med J Aust. 2015;203(5):221.e1–7. doi: 10.5694/mja15.00139 - DOI - PubMed
    1. Hand RM, Senarathna SMDKG, Page-Sharp M, Gray K, Sika-Paotonu D, Sheel M, et al.. Quality of benzathine penicillin G: A multinational cross-sectional study. Pharmacol Res Perspect. 2020;8(6):e00668. doi: 10.1002/prp2.668 - DOI - PMC - PubMed

MeSH terms

Substances